Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment

Schaffer, Charles B.; Schaffer, Linda C.

doi:10.1016/s0165-0327(98)00198-0

Cited by 30 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Open trials have also suggested the efficacy of topiramate as add‐on to mood‐stabilizers (level 3) (319, 320) or atypical antipsychotics (level 3) (306, 321). Ongoing, adjunctive gabapentin was effective for some patients who had responded to this agent acutely, but 30% of patients experienced a loss of efficacy over time (level 3) (322). In a 4‐month, RCT, omega‐3‐fatty acids prolonged the time in remission compared with placebo (level 2) (323).…”

mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

et al. 2005

View full text Add to dashboard Cite

Rev Bras Psiquiatr. 2006;28(1):80-5 83 Cartas aos editores consagram o lítio como primeira escolha terapêutica em pra-ticamente todas as fases e apresentações do TB. 5 Conclui-se que os psiquiatras (principalmente aqueles em formação) de-vem ser estimulados a conhecer de forma precisa as indica-ções do lítio e aprenderem a utilizar esta medicação, que tem auxiliado tantos pacientes. O legado do brilhante professor e pesquisador Mogens Schou, falecido recentemente, permanece mais atual do que nunca. Alegre (RS), Brasil Referências 1. Fieve RR. Lithium therapy at the millennium: a revolutionary drug used for 50 years faces competing options and possible demise. Bipolar Disord. 1999;1(2):67-70. 2. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17(4):250-60. 3. Schlagenhauf G, Tupin J, White RB. The use of lithium carbonate in the treatment of manic psychoses. Am J Psychiatry. 1966;123(2):199-207. 4. Sr. Editor, Nos últimos anos, a psiquiatria brasileira avançou muito no sentido de declarar todo e qualquer potencial conflito de interesse. No último congresso da Associação Brasileira de Psiquiatria (ABP), em Belo Horizonte (MG), todos os partici-pantes foram solicitados a declarar qualquer envolvimento comercial que pudesse, mesmo que remotamente, influen-ciar as suas apresentações. A própria Revista Brasileira de Psiquiatria (RBP) tem orientações muito claras para os auto-res quando da submissão dos artigos. Por isso, foi com grande surpresa que li, na última edição da RBP, o artigo do grupo do GREA-USP, 1 no qual não consta o reconhecimento de conflitos de interesse. É fato público que pelo menos dois dos autores desse artigo trabalham ou trabalharam na época da submissão do artigo numa ONG com financiamento da indústria do álcool (CISA). Na área da dependência química, várias das principais re-vistas internacionais têm códigos muito bem definidos sobre fontes de potencial conflitos de interesse, especialmente quan-do se trata de profissionais que aceitam financiamento da in-dústria do cigarro e do álcool. A declaração de haver, por parte dos profissionais, o envolvimento com a indústria do álcool ou do cigarro, lógico que não coloca necessariamente sob suspeita todo o eventual trabalho sério do ponto de vista científico. No entanto, acho que é um direito dos leitores da RBP saberem as eventuais fontes de conflitos de interesse para desenvolverem a sua própria opinião sobre a influência dessas indústrias na qualidade dos artigos publicados. Espero que os editores da RBP possam corrigir essa falta de informação.

show abstract

mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In on e study of 28 patient s, th e mean gabapen tin dos e was 539 mg/d ( 15). H ence, increasing dos es by 200 mg inst ead of300 mg may be more appropria te for mood stabi lization.…”

Section: Dosi Gmentioning

confidence: 95%

“…All other publ ish ed studies, consisting of op en trials whi ch have includ ed ga ba pe nt in bot h as monoth erapy and in addition to other psychotropic m edi cation s, have re ported effect ive improvem ent in th e majority of patients (13,15 ,17 ,18) . Mo st pati ents have d isp layed noticeable improvem ent in cycling activity with 200-3600 mg/d , th ou gh doses as low as 33 mg /d a nd as high as 4900 mg/d ha ve been re por te d ( 13,15). Ga ba pen tin may also have antidepressant effec ts: patients on th e new AED have noted im prove me nt in mood , m emory att ention , e ne rgy, slee p, and libido ( 10,13,17).…”

Section: Clinical Usementioning

confidence: 99%

See 1 more Smart Citation

Gabapentin in the Treatment of Bipolar Disorder

Waits¹,

Hall²

1998

JJP

View full text Add to dashboard Cite

“…A follow-up report of the 18 responding patients (17 women, age range 21-59 yrs) provided additional diagnostic information and patient demographics. 13 Seven patients were diagnosed with BD I, eight with BD II, and three with cyclothymic disorder. Seven patients continued gabapentin 100-2400 mg/day for an average of 33 months.…”

Section: Bipolar Disordermentioning

confidence: 99%

Gabapentin: A Review of Published Experience in the Treatment of Bipolar Disorder and Other Psychiatric Conditions

Letterman

Markowitz

1999

Pharmacotherapy

View full text Add to dashboard Cite

Successful therapy with valproate and carbamazepine in patients with psychiatric disorders led to investigation of other anticonvulsants for similar indications. Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders. Its favorable side effect profile, absence of the need for therapeutic drug monitoring, and minimal drug interactions give gabapentin a potential role in these indications. Computer searches of the biomedical literature were undertaken to identify all pertinent case reports, case series, and studies of the drug as monotherapy or adjunctive therapy for BD; 10 reports were retrieved. In the treatment of various anxiety disorders, one study, one case report, and one case series were identified. At least one case series described gabapentin therapy for alcohol withdrawal and one case report of the drug for agitation associated with dementia. Published, well-designed studies evaluating the agent's effectiveness as monotherapy for BD are lacking. Its benefit as an adjunctive treatment with other mood stabilizers is also unestablished. Data regarding its efficacy in the treatment of anxiety disorders or manifestations of substance abuse are limited. These areas may deserve further investigation.

show abstract

Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment

Cited by 30 publications

References 5 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

Gabapentin in the Treatment of Bipolar Disorder

Gabapentin: A Review of Published Experience in the Treatment of Bipolar Disorder and Other Psychiatric Conditions

Contact Info

Product

Resources

About